Tolerance and Prebiotic Activity of Arabinoxylan-Oligosaccharides in Healthy Subjects

This study has been completed.
Information provided by:
Katholieke Universiteit Leuven Identifier:
First received: February 26, 2009
Last updated: NA
Last verified: February 2009
History: No changes posted
The purpose of the study is to evaluate the tolerance of a higher dose of arabinoxylan-oligosaccharides (AXOS) and their prebiotic activity in healthy subjects.

Condition Intervention Phase
Dietary Supplement: arabinoxylan-oligosaccharides (AXOS)
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Crossover Assignment
Masking: Single Blind (Subject)
Primary Purpose: Treatment
Official Title: Tolerance and Prebiotic Activity of Arabinoxylan-Oligosaccharides in Healthy Subjects: a Randomized, Placebo-Controlled Cross-Over Study

Further study details as provided by Katholieke Universiteit Leuven:

Enrollment: 20
Study Start Date: October 2007
Study Completion Date: June 2008
Intervention Details:
    Dietary Supplement: arabinoxylan-oligosaccharides (AXOS)
    intake period: 3 weeks, 10 g/day

Ages Eligible for Study:   18 Years to 45 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • healthy
  • 18-45 years
  • regular eating pattern

Exclusion Criteria:

  • gastrointestinal complaints
  • antibiotic intake
  • medication influencing gut transit or microbiota
  • abdominal surgery
  • pregnancy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00852813

Department of Gastrointestinal Research, Laboratory Digestion and Absorption
Leuven, Belgium, 3000
Sponsors and Collaborators
Katholieke Universiteit Leuven
Study Director: Kristin Verbeke, PhD Katholieke Universiteit Leuven
  More Information

Responsible Party: Kristin verbeke, Katholieke Universiteit Leuven Identifier: NCT00852813     History of Changes
Other Study ID Numbers: AXOS 002
Study First Received: February 26, 2009
Last Updated: February 26, 2009
Health Authority: Belgium: Federal Agency for Medicinal Products and Health Products

Keywords provided by Katholieke Universiteit Leuven:
gastrointestinal effects processed this record on November 24, 2015